Case reports show durable responses in two patients with metastatic castration-resistant prostate cancer, suggesting abiraterone may enhance long-term survival.
We report two cases of metastatic castration‐resistant prostate cancer (mCRPC) with long‐term survival following treatment with abiraterone. Despite the generally temporary efficacy of abiraterone, both patients remained progression‐free for over 5 years, suggesting that some mCRPC patients may achieve durable responses with abiraterone.
No takes yet. Share an insight, caveat, or question.
Honoka Fuse (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: